Introduction: Tumor necrosis factor-a (TNF-a)
54.5% and 43.5%, respectively) that were very different from the findings in adalimumab-related encephalomyelitis in acute phase (11% and 89%, respectively). CSF cytology in two patients with neuromyelitis optica during the relapse (n = 3) showed minor monocyte/macrophage activation (9%) and an increased number of granulocytes (77% 
INTRODUCTION
Tumor necrosis factor-a (TNF-a) plays an important role in many aspects of immune system development, immune-response regulation, and T cell-mediated tissue injury, and is involved in many pathological conditions [1] . TNF-a inhibition represents a significant advance in the treatment of rheumatoid arthritis, and is approved for the treatment of ankylosing spondylitis and psoriatic arthritis, as well as Crohn's disease and ulcerative colitis [1] .
Tumor necrosis factor-a blocking agent adverse events include peripheral and central nervous system (CNS) demyelination [1] [2] [3] [4] [5] [6] [7] [8] ; however, the role of anti-TNF-a drugs in the development of demyelination has not yet been well defined. It is still a matter of debate whether TNF-a blocking agents could cause de novo nervous system demyelination or unmask latent disease, or whether the use of these drugs and the development of neurological disorders is coincidental [9, 10] 
CASE REPORT
Informed consent was obtained from the patient for being included in the study. A patient came to the authors' attention complaining of gait impairment and lower limb hypoesthesia, rapidly ascending up to the base of the neck, with dysesthesia and urinary hesitation. Symptoms had begun after the third injection of adalimumab, a recombinant human immunoglobulin (Ig) G1 monoclonal antibody that selectively binds TNF-a and blocks its interaction with the p55 and p75 cell surface TNF receptors [1] , that was prescribed for psoriatic arthritis. Neurological examination showed mild proximal weakness at the lower limbs and mild hypopallesthesia at the left lower limb.
The patient underwent brain and spinal magnetic resonance imaging (MRI): T2-weighted images showed a widespread area of hyperintense signal extending from C5 to D8 level and a clinically silent brain lesion adjacent to the left trigonum (Fig. 1) . Spinal cord diameters were slightly increased, mostly at C5-C7 levels (Fig. 1) . Both brain and spinal cord lesions were hyperintense on T1-weighted images after contrast enhancement. Two consecutive CSF examinations were performed: glucose and protein levels, and IgG index were in normal ranges, whereas cell count (45 and 43 cells/lL, respectively) and blood-CSF barrier permeability index (11.3 and 10.5, respectively) were increased. Oligoclonal bands were negative in both samples. A great number of activated cells of monocyte/macrophage lineage were present (88% and 90%, respectively), often forming large clusters. Prominent nucleoli were present in the majority of the clustered cells (Fig. 2a) . Moreover, some huge cells with irregular cellular membrane and eosinophilic, vacuolated cytoplasm were detected. Several cells showed a big kidney-shaped nucleus; notably a few cells presented two nuclei (Fig. 2b) .
Polymerase chain reaction (PCR) for HSV-1, HSV-2, VZV, and CMV was negative both in serum and CSF. Tuberculosis reactivation and meningeal carcinomatosis were excluded by X-ray of the chest, colonoscopy, serum 
DISCUSSION
Tumor necrosis factor-a, secreted by microglia and macrophages, has a critical role in demyelination [11] . A clinical trial in 1999
showed a worsening of the course in patients with MS during anti-TNF-a treatment [12] . Subsequently, central or peripheral nervous system demyelination was recognized as a well-known adverse event of anti-TNF-a therapy [1] [2] [3] [4] [5] [6] [7] [8] . In 2013, the Food and Drug
Administration Adverse Event Reporting System documented 772 cases of demyelinating diseases related to TNF-a antagonists, including 167 cases related to adalimumab [10] .
Tumor necrosis factor-a blocking agents could cause de novo nervous system demyelination or unmask latent disease, or the use of these drugs and the development of neurological disorders could be coincidental. and IgG index [3, 4, 7] . To the best of our knowledge, CSF cytology has not been reported.
In our case, CSF cytology showed a pattern that was different from CIS, MS, and NMO, being characterized by a great number of activated cells of monocyte/macrophage lineage with large kidney-shaped nucleus (88% and 90%, respectively, in two subsequent CSF analyses during the acute phase), often forming large clusters with lymphocytes; moreover, a few cells were binucleated. This pattern was clearly different from both CIS and MS that showed a similar increased percentage and activation of both lymphocyte and monocyte lineages. NMO is characterized, during acute phase of the disease, by the presence of granulocytes [13] . phenomenon occurring during granulomatous and herpetic infection [15] , that in our patient were excluded by negativity of both viral PCR detection and tuberculosis tests. In theory, the presence of binucleated cells would also require bone-marrow assessment, but this was not performed as CNS tumors in the course of anti-TNF therapy have never been reported [11, 16] . The mechanism causing the peculiar CSF pattern in our patient, that is a prominent activation of monocyte lineage, with increased number of macrophages and their fusion into binucleated cells during adalimumab treatment, is unknown; however, some data suggest an involvement of the CD36 receptor expressed on monocytes and a direct role of the monoclonal anti-TNF-a antibody [15, 17] . In fact it has been demonstrated that, while TNF-a inhibits, on the contrary, adalimumab increases CD36 membrane expression on human monocytes [17] and CD36 can cause macrophages fusion [15] . 
